Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Tafasitamab plus Lenalidomide as a Treatment in Patients With R/R DLBCL

July 7th 2022

Oncologists discuss the efficacy and safety of a tafasitamab plus lenalidomide for relapsed/refractory DLBCL and share personal experiences relevant to its use.

Defining Chronic or Persistent Immune Thrombocytopenia

July 7th 2022

Expert perspectives on how to identify chronic or persistent disease in patients diagnosed with immune thrombocytopenia.

Selecting Among Available Treatment Options for Patients With Relapsed/Refractory DLBCL

July 7th 2022

Caron Jacobson, MD, and Matthew Lunning, DO, FACP, assess the available treatment options for patients with R/R DLBCL.

The Significance of Patient Age in Treatment and Management of ITP

July 7th 2022

A commentary on the significance of the patient’s age in treating and managing ITP.

FDA Grants Priority Review to Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma

July 6th 2022

The FDA has accepted a biologics license application and granted a priority review designation to mosunetuzumab, a potential first-in-class CD20 and CD3 T-cell engaging bispecific antibody, for the treatment of patients with relapsed/refractory follicular lymphoma following at least 2 prior systemic therapies.

Review of the SELECT-AML-1 Trial and the Future of Newly Diagnosed AML

July 6th 2022

Daniel Pollyea, MD, MS, reviews the ongoing SELECT-AML-1 trial and comments on novel therapies and biomarkers in patients with newly diagnosed unfit AML.

Tisa-cel Adds a Potential New ‘Standard-of-Care’ in Third-Line Treatment of Follicular Lymphoma

July 6th 2022

Stephen J. Schuster, MD, discusses the implications of the FDA approval of tisagenlecleucel on the treatment strategy for relapsed/refractory follicular lymphoma and the next steps for tisa-cel.

Brexucabtagene Autoleucel Has Durable Efficacy in B-ALL, Irrespective of Age and Tumor Burden

July 4th 2022

Bijal Shah, MD, MS, discusses the long-term data from the ZUMA-3 trial of brexucabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia and spotlighted additional areas ripe for further exploration.

FDA Issues Warning for Increased Risk of Death, Serious AEs with Duvelisib in CLL/SLL

July 1st 2022

The FDA has warned that treatment with duvelisib has shown a possible increased risk of death and serious adverse effects compared with ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Grants Orphan Drug Designation to Evorpacept for AML

July 1st 2022

The FDA has granted an orphan drug designation to evorpacept, a next-generation CD47 blocker, for use as a potential therapeutic option for patients with acute myeloid leukemia.

FDA Approval Sought for Subcutaneous Epcoritamab for Relapsed/Refractory LBCL

July 1st 2022

Genmab A/S shared plans to submit a biologics license application to the FDA seeking the approval of subcutaneous epcoritamab for the treatment of patients with relapsed or refractory large B-cell lymphoma in the second half of 2022.

More Novel Therapies Are on the Horizon in Multiple Myeloma

July 1st 2022

Ajai Chari, MD, discusses the evolving landscape and developing therapies within multiple myeloma.

Improving Outcomes in Patients With DLBCL

June 30th 2022

Drs Locke and Gordon explain how outcomes for patients with DLBCL have improved as treatments continue to evolve.

A Focus on Frontline Treatment in Patients With DLBCL

June 30th 2022

Experts in lymphoma discuss how they risk stratify patients and the currently available options for first-line diffuse large-b cell lymphoma treatment.

Optimizing Frontline Therapy in ITP: Treatment Selection and Goals

June 30th 2022

Shared insight on treatment goals for immune thrombocytopenia and how physicians might optimally select frontline therapy.

Making a Diagnosis of Immune Thrombocytopenia

June 30th 2022

Opening their discussion on immune thrombocytopenia (ITP), expert panelists review criteria for diagnosis and highlight differences between adult and pediatric populations.

FDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma

June 29th 2022

The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

Orelabrutinib/Sintilimab Combo Induces Rapid Responses in Peripheral CNS Lymphoma

June 29th 2022

The addition of orelabrutinib to sintilimab demonstrated good efficacy with a rapid time to response in patients with relapsed/refractory primary central nervous system lymphoma.

CDK9 Inhibitor GFH009 Advances in Phase 1 Trial in Relapsed/Refractory Lymphoma and AML

June 28th 2022

The novel and highly selective CDK9 inhibitor GFH009 demonstrated encouraging tolerability in patients with advanced, relapsed/refractory acute myeloid leukemia and lymphoma.

Axi-cel Gains European Approval for Relapsed/Refractory Follicular Lymphoma

June 28th 2022

The European Commission has granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory follicular lymphoma after 3 or more prior lines of systemic therapy.